Global Oncology Radiopharmaceuticals Market Size To Exceed USD 7.25 Billion By 2035 | CAGR of 5.44%
Category: HealthcareGlobal Oncology Radiopharmaceuticals Market Size To Exceed USD 7.25 Billion By 2035
According to a research report published by Spherical Insights & Consulting, The Global Oncology Radiopharmaceuticals Market Size is expected to grow from USD 4.05 Billion in 2024 to USD 7.25 Billion by 2035, at a CAGR of 5.44% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Oncology Radiopharmaceuticals Market Size, Share, and COVID-19 Impact Analysis, By Test Type (Radium-223 dichloride, Sodium iodide I-131, Lobenguane iodide- 131, Lutetium-177, Yttrium-90, Fludeoxyglucose F 18, Gallium Citrate, and Technetium-99m), By Route of Administration (Oral and Treatment), By Application (Diagnosis and Treatment), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. " Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/oncology-radiopharmaceuticals-market
The oncology radiopharmaceuticals market refers to the pharmaceutical industry emphasizing the production of radioactive drugs for the diagnosis and treatment of cancer. Oncology radiopharmaceutical is a precision medicine approach that involves the targeted delivery of radioactive atoms to tumor cells, a breakthrough strategy for cancer treatment. Integration of radiopharmaceuticals with other therapeutic techniques, such as immunotherapy or chemotherapy, aids in improving patient outcomes. An increasing emphasis on early disease detection and personalized treatment is bolstering market growth opportunities. The rising need for efficient diagnostic & therapeutic options, along with an increasing cancer patient population, is driving the market. On the contrary, the lack of infrastructure and strict regulatory requirements are restraining the oncology radiopharmaceuticals market.
The technetium-99m segment dominated the market with a significant revenue share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the test type, the oncology radiopharmaceuticals market is divided into radium-223 dichloride, sodium iodide I-131, lobenguane iodide-131, lutetium-177, yttrium-90, fludeoxyglucose F 18, gallium citrate, and technetium-99m. Among these, the technetium-99m segment dominated the market with a significant revenue share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Technetium-99m is a radioactive tracer that is used in combination with special chemical agents for visualizing the tumor locations or metastatic disease. The growing prevalence of chronic diseases and technological advancements are driving the market for oncology radiopharmaceuticals.
The oral segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the route of administration, the Oncology Radiopharmaceuticals market is divided into oral and treatment. Among these, the oral segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Radiopharmaceuticals are usually administered in capsule or liquid form for both diagnostic and therapeutic purposes. Patients' increasing adoption and treatment compliance are contributing to driving market demand in the oral segment.
The diagnosis segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the application, the oncology radiopharmaceuticals market is divided into diagnosis and treatment. Among these, the diagnosis segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Radiopharmaceuticals enable accurate and timely cancer detection with improved resolution and provision of functional and metabolic information.
North America is expected to hold the majority share of the global oncology radiopharmaceuticals market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global oncology radiopharmaceuticals market during the forecast period. An increasing investment by the government bodies and local manufacturers for R&D activities and healthcare development contributes to driving the oncology radiopharmaceuticals market. Further, the prevalence of cancer, cardiovascular diseases, and neurological disorders in the region is driving market demand.
Asia Pacific is anticipated to grow at the fastest pace in the global oncology radiopharmaceuticals market during the forecast period. Development of technologies like PET/CT and SPECT systems for facilitating better diagnostic capabilities aids in propelling the oncology radiopharmaceuticals market. Further, increasing demand for advanced diagnostic and therapeutic solutions is also promoting market growth.
Major vendors in the global oncology radiopharmaceuticals market are Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, Cardinal Health, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In April 2025, Bayer announced the initiation of a Phase I clinical trial with Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma (HCC).
- In October 2024, ITM Isotope Technologies Munich SE (ITM), the Technical University of Munich (TUM), and the TUM University Hospital (Klinikum rechts der Isar der Technischen Universität or MRI), announced a new framework agreement for the research and development of innovative radiopharmaceuticals and radionuclides for the treatment of cancer.
- In May 2024, Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, announced it would be acquired by Novartis for $1 billion upfront and up $750 million in potential milestone payments.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Oncology Radiopharmaceuticals market based on the below-mentioned segments:
Global Oncology Radiopharmaceuticals Market, By Test Type
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodide- 131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate
- Technetium-99m
Global Oncology Radiopharmaceuticals Market, By Route of Administration
- Oral
- Intravenous
Global Oncology Radiopharmaceuticals Market, By Application
- Diagnosis
- Treatment
Global Oncology Radiopharmaceuticals Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?